首页> 美国卫生研究院文献>Journal of Thoracic Disease >Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?—An update incorporating the DELTA trial data

【2h】

Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?—An update incorporating the DELTA trial data

机译：EGFR未选择人群晚期非小细胞肺癌的化学疗法与酪氨酸激酶抑制剂的治疗尚有争议吗？—结合DELTA试验数据的更新

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 Journal of Thoracic Disease
作者
Marina C. Garassino; Massimo Broggini;
展开▼
作者单位

展开▼
年(卷),期 2015(7),3
年度 2015
页码 224–226
总页数 3
原文格式 PDF
正文语种
中图分类呼吸生理学;
关键词

相似文献

外文文献
中文文献
专利

1. 第一代EGFR酪氨酸激酶抑制剂治疗106例复合EGFR突变肺癌患者:一项单中心临床研究 [J] . Xiangyang Yu, Xuewen Zhang, Zichen Zhang, 癌症（英文版） . 2019,第010期
2. Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?—An update incorporating the DELTA trial data [J] . Marina C. Garassino, Massimo Broggini Journal of Thoracic Disease . 2015,第3期

机译：EGFR未选择人群晚期非小细胞肺癌的化学疗法与酪氨酸激酶抑制剂的治疗尚有争议吗？—结合DELTA试验数据的更新
3. Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer [J] . Gray Jhanelle E., Okamoto Isamu, Sriuranpong Virote, Clinical cancer research: an official journal of the American Association for Cancer Research . 2019,第22期

机译：Flaura试验中的组织和血浆EGFR突变分析：Osimertinib与比较器EGFR酪氨酸激酶抑制剂作为EGFR-突变的晚期非小细胞肺癌患者的一线治疗
4. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [J] . Hasegawa Yoshikazu, Ando Masahiko, Maemondo Makoto, The oncologist . 2015,第3期

机译：吸烟状态在非活化小细胞肺癌患者无进展生存中的作用，该患者具有接受一线EGFR酪氨酸激酶抑制剂与铂类双重治疗的活化表皮生长因子受体（EGFR）突变：前瞻性随机试验的荟萃分析。
5. Association between tumor heterogeneity and progression-free survival in non-small cell lung cancer patients with EGFR mutations undergoing tyrosine kinase inhibitors therapy [C] . Jiangdian Song, Di Dong, Yanqi Huang, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2016

机译：接受酪氨酸激酶抑制剂治疗的EGFR突变非小细胞肺癌患者肿瘤异质性与无进展生存的关系
6. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
7. The Role of Smoking Status on the Progression-Free Survival of Non-Small Cell Lung Cancer Patients Harboring Activating Epidermal Growth Factor Receptor (EGFR) Mutations Receiving First-Line EGFR Tyrosine Kinase Inhibitor Versus Platinum Doublet Chemotherapy: A Meta-Analysis of Prospective Randomized Trials [O] . Yoshikazu Hasegawa, Masahiko Ando, Makoto Maemondo, 2015

机译：吸烟状态在非小细胞肺癌患者无进展生存中的作用该患者具有接受一线EGFR酪氨酸激酶抑制剂对铂类双重化疗的活化表皮生长因子受体（EGFR）突变：前瞻性随机试验的Meta分析。
8. 481TiP Checkmate 722: A phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy [O] . K. Nakagawa, J.C.-H. Yang, K. Park, 2016

机译：481tip Checkmate 722：在EGFR酪氨酸激酶抑制剂（Tki ）治疗

Chemotherapy versus tyrosine kinase inhibitor in EGFR unselected population advanced non-small cell lung cancer still matter of debate?—An update incorporating the DELTA trial data

著录项

引文网络

相似文献

相关主题

期刊订阅